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Abstract: In severe acute pancreatitis (SAP), systemic inflammation leads to endothelial dysfunction
and activation of coagulation. Thrombotic disorders in acute pancreatitis (AP) include disseminated
intravascular coagulation (DIC). Recently, angiopoietin-2 and soluble fms-like tyrosine kinase 1
(sFlt-1) were proposed as markers of endothelial dysfunction in acute states. Our aim was to
assess the frequency of coagulation abnormalities in the early phase of AP and evaluate the
relationships between serum angiopoietin-2 and sFlt-1 and severity of coagulopathy. Sixty-nine
adult patients with AP were recruited: five with SAP, 15 with moderately severe AP (MSAP)
and 49 with mild AP. Six patients were diagnosed with DIC according to International Society
on Thrombosis and Haemostasis (ISTH) score. All patients had at least one abnormal result of routine
tests of hemostasis (low platelet count, prolonged clotting times, decreased fibrinogen, and increased
D-dimer). The severity of coagulopathy correlated with AP severity according to 2012 Atlanta criteria,
bedside index of severity in AP and duration of hospital stay. D-dimers correlated independently
with C-reactive protein and studied markers of endothelial dysfunction. Angiopoietin-2, D-dimer,
and ISTH score were best predictors of SAP, while sFlt-1 was good predictor of MSAP plus SAP.
In clinical practice, routine tests of hemostasis may assist prognosis of AP.
Int. J. Mol. Sci. 2017, 18, 753; doi:10.3390/ijms18040753 www.mdpi.com/journal/ijms
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1. Introduction
Acute pancreatitis (AP) is an inflammatory disorder, characterized by a spectrum of
severity, ranging from mild disease in most patients, to severe life-threatening condition [1,2].
Current guidelines [3] classify the disease course as mild (MAP), moderately-severe (MSAP) and severe
AP (SAP) on the basis of organ failure (transient or persistent), and local and systemic complications.
Organ failure (including cardiovascular, pulmonary and renal) occurring in the early phase of AP is
the most important determinant of severity and the main cause of early deaths [3]. Severe course of
AP is associated with excessive systemic inflammation, involving systemic activation and dysfunction
of endothelial cells, leading to vascular leak syndrome and organ failure [4].
Angiopoietin-2 and soluble fms-like tyrosine kinase 1 (sFlt-1) have been proposed as novel
predictors of severity in acute states, such as sepsis or AP [5–11]. Angiopoietin-2 is an angiogenic
growth factor, binding and inhibiting Tie-2 receptor on endothelial cells, which has been associated
with destabilization of endothelium and increased vascular leakage [12,13]. Flt-1 is a receptor for
vascular endothelial growth factor and placental growth factor, its soluble form (sFlt-1) acts as a decoy
receptor [14]. Both angiopoietin-2 and sFlt-1 may be considered markers of endothelial dysfunction
in acute states. We have previously reported the associations between serum concentrations of
angiopoietin-2 and the development of acute kidney injury and renal failure in the course of AP as
well as the severity of AP [7]. In addition, we have reported the association between serum sFlt-1
concentrations in the early phase of AP and the severity of the disease [8].
Endothelial dysfunction may result in activation of platelets and coagulation. Clinically significant
hemorrhagic and thrombotic disorders were observed, respectively, among 6% and 7% of patients
who died due to AP [15]. Several coagulopathies were reported as the complications of AP, including
among others disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic
purpura [16–19]. The results of laboratory tests used to assess hemostasis were shown to predict
severity of AP and related mortality with reasonable diagnostic utility, in some reports exceeding those
observed for C-reactive protein [16,20]. In particular, high diagnostic accuracy to predict SAP was
reported for D-dimer plasma concentrations [16,20–23].
The aim of the study was to assess the frequency of coagulopathy in a cohort of consecutive
patients with AP in the early phase of the disease. Moreover, we studied the associations between
the serum concentrations of angiopoietin-2 and sFlt-1 and the presence as well as the severity of
abnormalities of coagulation in the early phase of AP.
2. Results
Sixty-nine patients (35 men and 34 women; mean age 69 ± 18) were included in the study, among
them 49 were diagnosed with MAP, 15 with MSAP, and 5 with SAP.
During the first 48 h of AP, six patients (7% of the total cohort) were assigned six points or more
in the International Society on Thrombosis and Haemostasis (ISTH) score for overt DIC [24], thus
fulfilling the criteria of overt DIC. The diagnosis of DIC was significantly associated with more severe
AP, higher bedside index of severity in AP (BISAP) [25] and Glasgow [26] severity scores, longer
hospital stays, and higher mortality (Table 1). Patients subsequently diagnosed with DIC had longer
prothrombin times and higher plasma concentrations of D-dimer at admission, as well as higher serum
urea (Table 1).
Twenty-one healthy volunteers (12 women and nine men; mean age 51 ± 10 years) provided serum
samples in order to compare angiopoietin-2 and sFlt-1 concentrations between healthy controls and AP
patients. In the control group, angiopoietin-2 concentrations were in the range of 1.17–2.41 ng/mL with
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median (lower-upper quartile) of 1.69 (1.44–2.08) ng/mL and sFlt-1 concentrations were in the range of
63–108 pg/mL with median (lower-upper quartile) of 89 (79–94) pg/mL. Both angiopoietin-2 (p < 0.001
at 24 h and p < 0.001 at 48 h) and sFlt-1 (p < 0.001 at 24 h and p < 0.001 at 48 h) were significantly higher
in AP patients than in controls (Figure 1). In multiple logistic regression, these differences between AP
patients and controls were independent of age. The concentrations of angiopoietin-2 and sFlt-1 were
also significantly higher among AP patients with DIC comparing to patients without DIC, both on
admission and on the second day of hospital stay (Table 1, Figure 1).
Table 1. Clinical characteristics of patients and the results of laboratory tests performed at 24 h from
the onset of acute pancreatitis (AP) symptoms.
Variables Patients without DIC(N = 63)
Patients with DIC
(N = 6) p
Age, years 59 ± 18 71 ± 16 0.1
Male sex, N (%) 31 (49) 4 (67) 0.4
Body mass index >30 kg/m2 2 (3) 0 0.7
Etiology:
Gallstone, N (%) 32 (51) 3 (50) 0.9
Alcohol, N (%) 17 (27) 1 (17)
Hypertriglyceridemia, N (%) 6 (10) 1 (17)
Other/idiopathic, N (%) 8 (13) 1 (17)
Severity:
MAP, N (%) 48 (76) 1 (17) 0.003
MSAP, N (%) 12 (19) 3 (50)
SAP, N (%) 3 (5) 2 (33)
Pre-existing comorbidities, N (%) 48 (76) 6 (100) 0.2
Hypertension, N (%) 21 (33) 2 (33) 1.0
Diabetes, N (%) 9 (14) 1 (17) 0.9
Ischemic heart disease, N (%) 15 (24) 3 (50) 0.2
Lung diseases, N (%) 6 (10) 2 (33) 0.08
BISAP score, points 1 (0–1) 2 (1–2) 0.019
Glasgow severity score, points 0 (0–1) 2 (1–3) 0.035
SIRS, N (%) 8 (13) 1 (17) 0.8
Length of hospital stay, days 6 (5–9) 10 (8–31) 0.013
Early/late death, N (%) 0/1 (2) 0/2 (33) 0.018
C-reactive protein, mg/L 13.6 (2.6–86.7) 36.3 (13.7–84.5) 0.3
Leukocyte count, ×103/µL 11.4 (9.6–15.4) 10.8 (9.8–11.2) 0.3
Hematocrit, % 42 ± 5 42 ± 5 1.0
Amylase, U/L 1076 (588–1844) 976 (925–1917) 0.9
Albumin, g/L 40 (37–43) 41 (34–42) 0.7
Calcium, mmol/L 2.35 (2.20–2.43) 2.29 (2.18–2.38) 0.8
Glucose, mmol/L 7.76 (6.43–10.29) 10.15 (7.79–12.25) 0.2
Creatinine, µmol/L 74.2 (63.4–97.6) 101.7 (76.0–113.4) 0.1
Urea, mmol/L 5.94 (4.26–7.08) 8.04 (6.72–12.73) 0.036
Bilirubin, µmol/L 36.0 (21.1–71.4) 36.8 (32.5–59.9) 0.9
Platelet count, ×103/µL 229 ± 60 227 ± 102 0.9
Prothrombin time, s 14.4 ± 1.6 16.1 ± 1.2 0.015
APTT, s 29.5 ± 4.8 29.9 ± 6.1 0.8
Fibrinogen, g/L 2.78 (2.15–3.58) 3.18 (2.75–4.46) 0.4
D-dimer, µg/mL 1.61 (0.98–3.09) 3.99 (2.10–13.89) 0.019
Angiopoietin-2, ng/mL 3.06 (2.05–4.29) 4.97 (3.59–5.92) 0.037
sFlt-1, pg/mL 182 (163–221) 139 (110–179) 0.041
Abbreviations: DIC, diffuse intravascular coagulation; N, number of patients; MAP, mild acute pancreatitis; MSAP,
moderately severe acute pancreatitis; SAP, severe acute pancreatitis; BISAP, bedside index of severity in acute
pancreatitis; SIRS, systemic inflammatory response syndrome; APTT, activated partial thromboplastin time; sFlt-1,
soluble fms-like tyrosine kinase 1.
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Figure 1. Serum angiopoietin-2 and sFlt-1 concentrations on: admission (A,D); and on Day 2 of 
hospital stay (B,E), among acute pancreatitis (AP) patients with ISTH score for overt DIC below 5 (no 
DIC) and ≥5 points (DIC). Serum: angiopoietin-2 (C); and sFlt-1 (F) concentrations observed among 
21 healthy controls are presented for comparison. Data are shown as median, interquartile range 
(box), non-outlier range (whiskers), and outliers (points). Abbreviations: sFlt-1, soluble fms-like 
tyrosine kinase 1; DIC, diffuse intravascular coagulation; ISTH, International Society on Thrombosis 
and Haemostasis. 
The abnormal results of routine tests of hemostasis, suggestive of consumptive coagulopathy, 
were significantly associated with AP severity. On admission, low platelet counts were observed in 
60% of patients with SAP, 13% with MSAP and 6% with MAP; prothrombin time was prolonged in 
80% of patients with SAP, 13% with MSAP and 22% with MAP; and activated partial thromboplastin 
time (APTT) was prolonged in 60% of those with SAP, 20% with MSAP and none patients with MAP 
(Figure 2A,C,E, respectively). Following treatment, these differences became non-significant already 
on Day 2 of hospital stay (Figure 2B,D,F). No significant associations were detected between AP 
severity and fibrinogen concentrations, however, patients with SAP tended towards high 
concentrations (Figure 3A,B). High concentrations of D-dimer were associated with more severe AP 
both at 24 and 48 h after the onset of AP symptoms. Severely increased D-dimer levels (>5 µg/mL) 
were observed in 80% of patients with SAP, 13% of those with MSAP and 6% with MAP on Day 1, 
and 80% of patients with SAP, 47% with MSAP, and 10% with MAP on Day 2, respectively (Figure 
2C,D). Consequently, significantly higher results in ISTH score for overt DIC were observed in SAP 
and MSAP patients versus those with MAP (Figure 2E,F). On Day 2 of AP, 40% of patients with SAP, 
20% of those with MSAP and 2% with MAP were assigned ≥5 points in ISTH score, supporting the 
diagnosis of overt DIC. Consistent with the fact that D-dimer concentrations were increased above 
the reference limit (0.5 µg/mL) in all the studied patients (except for one lower result achieved on 
admission), the lowest ISTH score among studied patients was 2 points. 
Figure 1. Serum angiopoietin-2 and sFlt-1 concentrations on: admission (A,D); and on Day 2 of hospital
stay (B,E), among acute pancreatitis (AP) patients with ISTH score for overt DIC below 5 (no DIC) and
≥5 points (DIC). Serum: angiopoietin-2 (C); and sFlt-1 (F) concentrations observed among 21 healthy
controls are presented for comparison. Data are shown as median, interquartile range (box), non-outlier
range (whiskers), and outliers (points). Abbreviations: sFlt-1, soluble fms-like tyrosine kinase 1; DIC,
diffuse intravascular coagulation; ISTH, International Society on Thrombosis and Haemostasis.
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Figure 2. Numbers of patients with platelet counts (A,B); prothrombin times (C,D); and activated 
partial thromboplastin times (APTT) (E,F) below (low), within (normal) and above (high) the 
reference intervals. Panels A, C and E show the results obtained at 24 h and Panels B, D and F at 48 h 
from the onset of AP symptoms. Numbers of patients with mild AP (MAP), moderately severe AP 
(MSAP) and severe AP (SAP) are represented by dark, medium and light boxes, respectively; 
p-values for the chi-squared tests are shown on the graphs. 
Figure 2. Numbers of patients with platelet counts (A,B); prothrombin times (C,D); and activated
partial thromboplastin times (APTT) (E,F) below (low), within (normal) and above (high) the reference
intervals. Panels A, C and E show the results obtained at 24 h and Panels B, D and F at 48 h from the
onset of AP symptoms. Numbers of patients with mild AP (MAP), moderately severe AP (MSAP)
and severe AP (SAP) are represented by dark, medium and light boxes, respectively; p-values for the
chi-squared tests are shown on the graphs.
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Figure 3. Numbers of patients with fibrinogen concentrations below (low), within (normal) and above
(high) the reference interval (A,B); with D-dimer concentrations below reference limit (<0.5 µg/mL),
increased up to 10 times (0.5–5.0 µg/mL) and increased more than 10 times (> 5. 0 µg/mL) (C,D); and
with ISTH score for overt DIC of 2, 3, and more than 3 points (E,F). Panels A, C and E show the results
obtained at 24 h and Panels B, D and F at 48 h from the onset of AP symptoms. Numbers of patients
with MAP, MSAP and SAP are represented by dark, medium and light boxes, respectively; p-values for
the chi-squared tests are shown on the graphs.
Positive correlations were observed between log-transformed C-reactive protein and fibrinogen
concentrations (R = 0.54; p < 0.001 on Day 1 and R = 0.27; p = 0.025 on Day 2), D-dimer (R = 0.45;
p < 0.001 on Day 1 and R = 0.64; p < 0.001 on Day 2), APTT (R = 0.33; p = 0.007 on Day 1), and ISTH
score (R = 0.29; p = 0.017 on Day 1 and R = 0.49; p < 0.001 on Day 2). Only fibrinogen concentrations
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correlated with amylase activity (for log-transformed variables: R = −0.32; p = 0.010 on Day 1).
On admission, log-transformed D-dimer (R = 0.51; p < 0.001), APTT (R = 0.34; p = 0.005), platelet count
(R = −0.29; p = 0.017) and ISTH score (R = 0.43; p < 0.001) significantly correlated with BISAP score,
and log (D-dimer) (R = 0.34; p = 0.004), platelet count (R = −0.33; p = 0.006) and ISTH score (R = 0.24;
p = 0.049) significantly correlated with Glasgow score. Moreover, log (fibrinogen) (R = 0.27; p = 0.028
on admission), log (D-dimer) (R = 0.46; p < 0.001 on Day 1 and R = 0.59; p < 0.001 on Day 2), and ISTH
score (R = 0.38; p = 0.001 on Day 1 and R = 0.44; p < 0.001 on Day 2) positively correlated with the
duration of hospital stay.
Serum angiopoietin-2 and sFlt-1 concentrations positively correlated with D-dimer and ISTH
score (Table 2). Additionally, angiopoietin-2 significantly correlated with APTT and fibrinogen on
Day 1 as well as with platelets and prothrombin time on Day 2, while sFlt-1 significantly correlated
with prothrombin time on Day 2 (Table 2). The correlations between angiopoietin-2 concentrations and
D-dimer were independent of C-reactive protein concentrations (β = 0.29 ± 0.13; p = 0.029 on Day 1,
and β = 0.32 ± 0.09; p = 0.001 on Day 2). In addition, sFlt-1 correlated with D-dimer independently of
C-reactive protein (β = 0.27 ± 0.12; p = 0.029 on Day 1 and β = 0.25 ± 0.12; p = 0.042 on Day 2).
Table 2. Correlations between angiopoietin-2 and sFlt-1 concentrations (log-transformed) and the
results of the tests of hemostasis at 24 and 48 h from the onset of AP symptoms.
Variables
24 h 48 h
log (Ang-2) log (sFlt-1) log (Ang-2) log (sFlt-1)
R p R p R p R p
Platelet count −0.18 0.2 −0.16 0.3 −0.30 0.015 −0.21 0.1
Prothrombin time 0.22 0.08 0.06 0.7 0.25 0.042 0.38 0.003
APTT 0.53 <0.001 0.19 0.2 −0.01 0.9 0.23 0.06
log (fibrinogen) 0.33 0.008 0.09 0.5 0.18 0.2 −0.04 0.8
log (D-dimer) 0.45 <0.001 0.40 <0.001 0.48 <0.001 0.27 0.028
ISTH score for overt DIC 0.33 0.008 0.40 <0.001 0.37 0.003 0.50 <0.001
Abbreviations: Ang-2, angiopoietin-2; sFlt-1, soluble fms-like tyrosine kinase 1; APTT, activated partial
thromboplastin time; DIC, diffuse intravascular coagulation; ISTH, International Society on Thrombosis
and Haemostasis.
On admission, the results of all the studied tests of hemostasis and both the endothelial markers
enabled the prognosis of SAP, although the diagnostic utility differed between the tests (Table 3).
Among the routine tests of hemostasis, D-dimer revealed the best diagnostic utility for the prediction of
severity of AP (Table 3). However, the highest values of area under the receiver operating characteristic
(ROC) curves were achieved for angiopoietin-2 as a predictor of SAP, and for sFlt-1 as a predictor of
MSAP+SAP (Table 3). At 24 h from the onset of AP symptoms, angiopoietin-2 at a cut-off value of
5.92 ng/mL predicted SAP with a diagnostic sensitivity of 100% and specificity of 92%; ISTH score at a
cut-off value of 3 points predicted SAP with a diagnostic sensitivity of 100% and specificity of 81%;
and D-dimer at a cut-off value of 6.55 µg/mL predicted SAP with a diagnostic specificity of 80% and
sensitivity of 94% (Figure 4).
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Table 3. The values of area under the ROC curve for the studied laboratory tests of hemostasis
and markers of endothelial dysfunction measured on admission (within 24 h from the onset of AP
symptoms) to predict the severity of AP (diagnosis of SAP or MSAP+SAP versus less severe AP).
The data for C-reactive protein are shown for comparison.
Diagnostic Tests SAP MSAP+SAP
Platelet count 0.803 ± 0.126 NS
Prothrombin time 0.830 ± 0.068 NS
APTT 0.768 ± 0.126 NS
Fibrinogen 0.788 ± 0.105 NS
D-dimer 0.902 ± 0.062 0.753 ± 0.070
ISTH score for overt DIC 0.913 ± 0.037 0.702 ± 0.077
Angiopoietin-2 0.946 ± 0.029 0.721 ± 0.077
sFlt-1 0.744 ± 0.064 0.810 ± 0.059
C-reactive protein 0.886 ± 0.064 0.733 ± 0.066
NS, no significant difference between the area under the ROC curve calculated for the particular test and the
value of 0.5. Abbreviations: AP, acute pancreatitis; SAP, severe acute pancreatitis; MSAP, moderately severe acute
pancreatitis; ROC, receiver operating characteristic; APTT, activated partial thromboplastin time; ISTH, International
Society on Thrombosis and Haemostasis; DIC, diffuse intravascular coagulation; sFlt-1, soluble fms-like tyrosine
kinase 1; BISAP, bedside index of severity in acute pancreatitis.
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3. Discussion
In the pres nt study, we have shown t t i ted ith abnormal ties of coagulation
leading to abnormal results of routinely us stasis. Of importance, we have exclu ed
patients with preexisti or alities of coagulatio a d n ne of our patients were treated
with anticoagulants before or during the study. Low platelet counts, prolonged prothrombin
times, prolonged APTT, and increased D-dimer concentrations observed in our patients suggest
consumptive coagulopathy. Six patients (7% of the group) fulfilled the ISTH criteria for overt
DIC [24]. These abnormalities correlated with both inflammation (as reflected by C-reactive protein
concentrations) and endothelial dysfunction (as reflected by the concentrations of angiopoietin-2 and
sFlt-1). Abnormal results of coagulation tests on admission were significantly associated with severity
of AP, in particular, high plasma concentrations of D-dimer as well as ISTH score for DIC predicted
more severe AP (SAP or MSAP+SAP) with reliable diagnostic accuracy.
These observations are consistent with the results of former studies. In 2006, Maeda et al. [16]
reported significant associations between the results of laboratory tests of hemostasis (including
platelet counts, antithrombin activity, and the concentrations of D-dimer, fibrin/fibrinogen degradation
products E, and thrombin–antithrombin complexes) and severity of AP assessed in 5-stage Japanese
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staging system for AP. In that study, low platelet count, low antithrombin activity, and high
concentrations of thrombin–antithrombin complexes and fibrin formation markers (fibrin/fibrinogen
degradation product E and D-dimers) predicted death from AP with reliable diagnostic accuracy
(the areas under the ROC curves between 0.768 for thrombin–antithrombin complexes and 0.926 for
antithrombin activity) [16]. In addition, Radenković et al. [20] reported high diagnostic accuracy
(areas under the ROC curves of 0.908 and 0.915, respectively) for D-dimer measured at admission and
24 h thereafter in the prognosis of organ failure complicating AP (pulmonary, renal failure or shock).
More recently, Ke et al. [22] studied a prospective cohort of 173 patients with AP of whom 47 were
diagnosed with critical AP (persistent organ failure plus infected pancreatic necrosis). D-dimer was
found to be a significant predictor of critical AP (area under the ROC curve was 0.810), in contrast to
C-reactive protein. Several smaller studies reported D-dimer to be a marker of severe complications,
i.e., multiorgan failure or pancreatic infection or death in the course of AP [21,27,28]. On the other
hand, D-dimer was also reported to significantly predict MSAP diagnosed in accordance with revised
2012 Atlanta classification [29]. Consequently, a recent position paper following the international
meeting of the American Pancreatic Association and the Japanese Pancreas Society includes D-dimer
in a proposed AP activity index [4]. However, from practical point of view, the lack of standardization
of D-dimer measurements leads to difficulties in the interpretation of results [30]. This is reflected by
discrepant cut-off values reported in the studies cited above, from 0.4 to about 1.2 µg/mL in most
studies [20–22,27,28] and even as high as 6.1 µg/mL in the study of Maeda et al. [16]. In fact, our
results confirm the data of Maeda et al. [16].
Of interest, in our study, the results of functional coagulation tests, i.e., prothrombin time, APTT
and fibrinogen were associated with AP severity on admission and the associations became weaker
or non-significant a day thereafter, while the highly significant association between D-dimer and AP
severity persisted at 48 h from the onset of AP. One explanation may be that the functional tests are
more influenced by the treatment of AP. In in the early phase of AP, intensive fluid resuscitation is
introduced [2,4]. On the other hand, all patients in our study exhibited at least one abnormal result
of coagulation tests, and the severity of coagulopathy as detected by the laboratory tests progressed
from 24 to 48 h of AP. Thus, it seems that, in patients with more severe AP, coagulopathy develops
earlier and is detectable already on admission while those with mild AP also develop some coagulation
abnormalities but they became evident later.
The diagnosis of DIC is not always straightforward. Several scores are used that include the
results of routine and, in some cases, also of less accessible laboratory tests [31]. In our study, we
decided to use ISTH score for overt DIC, the one based on the results of routine and easily available
tests [24]. Organ destruction such as pancreatitis is listed among the conditions associated with
DIC, allowing the use of the clinical/laboratory scores for the diagnosis of DIC [24,31]. Indeed,
several authors reported clinically significant DIC as a complication of AP [16,18,32]. However, other
coagulopathies were also observed in the course of AP, such a localized thrombosis and pulmonary
embolism [33–37] or thrombotic thrombocytopenic purpura [17,38]. The diagnosis of DIC in AP
patients is further complicated by the fact that acute inflammation is a known factor leading to an
increase in platelet counts [39], fibrinogen, and D-dimer concentrations [30]. Thus, in the early phase of
AP, platelet counts and fibrinogen concentrations may increase due to inflammation and decrease due
to consumptive coagulopathy; single laboratory result would be influenced by both processes. This is
reflected by increased, rather than deceased fibrinogen observed in our cohort, including patients with
SAP. As a positive acute phase protein, fibrinogen is highly influenced by inflammation, being the
least sensitive marker of DIC in acute inflammatory conditions.
The pathomechanisms of activation of coagulation in AP are complex. Microvascular involvement
is an important part of early pathogenesis of AP. SAP is characterized by significantly decreased blood
flow in the capillaries of the pancreas [40,41], however, decreased blood flow velocity, increased
vascular permeability and microvascular thrombosis are also observed in distant organs, including
lungs, kidney and liver [42,43]. In 1970s, the release of proteolytic enzymes from damaged pancreas
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has been suggested as a causative factor for coagulopathy in AP [44]. At present, it is rather thought,
that the activation or dysfunction of vascular endothelium in consequence of acute inflammation
leads to procoagulant changes, including (but not confined to) the expression of tissue factor on
endothelial cells, constituting the main trigger for activation of coagulation (extensively reviewed
in [23]). Although indirectly, our results seem to support this assumption: in our cohort, significant
correlations were found between D-dimer and inflammatory marker (C-reactive protein) as well as the
markers of endothelial dysfunction (angiopoietin-2 and sFlt-1), but not between D-dimer and amylase
activity. Of note, the associations between inflammation, coagulation and endothelial dysfunction are
complex and reciprocal. The results of experimental studies in AP raise hope that these detrimental
interactions may be in part inhibited with anticoagulant treatment [23,45–48].
The present report supplements our earlier reports regarding angiopoietin-2 [7] and sFlt-1 [8]
as the markers of severity in AP; hereby we show (pathophysiologically relevant) associations of
these endothelial markers with coagulopathy in AP. There is a body of evidence showing that high
concentrations of angiopoietin-2 predicts more severe AP [5,6] and our results are consistent with
these reports. To the contrary, according to our knowledge, our reports are the only ones showing the
association between high sFlt-1 concentrations and AP severity. In 2011, Espinosa et al. [49] evaluated
the relationships between soluble angiogenesis-related markers including soluble vascular endothelial
growth factor receptor-1 (or sFlt-1) and AP severity and did not found the significant association.
However, the discrepancy between the results of Espinosa et al. and ours may be explained by the
different time-points of sample collection (Espinosa et al. took the blood samples considerably later
after onset of AP symptoms than we did) and by the differences in laboratory methods. On the other
hand, sFlt-1 proved useful in prediction of the severity of sepsis [9]. Still, further studies are definitely
necessary to evaluate the usefulness of sFlt-1 in prediction of AP severity; such studies are especially
awaited as the availability of an automated sFlt-1 assay would make it easier to introduce the marker
into clinical practice.
Several limitations of our study must be admitted. First, low number of patients with SAP
makes it impossible to draw definitive conclusions regarding diagnostic utility of studied tests to
predict SAP. These results must be treated as hypothesis-generating and needs further evaluation
in larger sample. Second, we have not measured other markers of endothelial activation or
dysfunction. The degranulation of Weibel-Palade bodies of activated endothelial cells leads to the
increase in plasma/serum concentrations of numerous bioactive substances besides angiopoietin-2,
e.g., von Willebrand factor, interleukin-8, endothelin-1, or P-selectin [23]. The associations we have
observed among angiopoietin-2, sFlt-1, coagulation abnormalities and more severe course of AP might,
in fact, be mediated by other bioactive compounds. Still, this fact does not exclude the possibility for
the use of the studied markers in clinical practice. Third, although we have investigated and presented
the most important demographic and clinical characteristics of patients, including data on etiology of
AP, and comorbidities, there are numerous unmeasured confounders that may influence our results,
including diet, lifestyle and genetic factors that may influence the development of pancreatitis [50],
as well as the inflammatory response [51] and the severity of coagulopathy [52].
In conclusion, our study shows that the abnormalities of coagulation are present already in the
very early phase of AP (first 24 h from the onset of symptoms). The coagulopathy is associated with the
severity of inflammation and endothelial dysfunction. Thus, the results of routine tests of hemostasis,
and in particular, the measurement of D-dimer, may assist the prognosis of AP severity and should
be taken into account in clinical practice. Although our results regarding the diagnostic utility of
studied tests for the diagnosis of SAP must be treated with caution due to low number of patients with
SAP, our data support the promising reports on angiopoietin-2 as an early marker of SAP. In contrast,
concentrations of sFlt-1 in early phase of AP seem to predict both transient and persistent organ failure,
as reflected by reasonable diagnostic accuracy for the diagnosis of MSAP plus SAP. There is a need
for novel markers with high diagnostic accuracy to predict severity of AP, and the studied markers of
vascular leakage and endothelial dysfunction seem promising in this setting, however, especially in
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case of sFlt-1, more studies are needed to verify our results. In the meantime, our results underscore
the value of laboratory assessment of coagulation in clinical practice: coagulopathy detected by routine
tests may be viewed as a surrogate marker of endothelial dysfunction among patients with AP.
4. Materials and Methods
4.1. Study Protocol
The prospective observational study recruited a cohort of consecutive adult patients admitted with
the diagnosis of AP and treated in the Surgery Department of the District Hospital in Sucha Beskidzka,
Poland. AP was diagnosed in concordance with 2012 revision of the Atlanta Classification [3],
i.e., when two of the three following criteria were fulfilled: abdominal pain consistent with AP,
serum amylase activity above three times greater than the upper reference limit, and characteristic
findings of AP on abdominal imaging (contrast-enhanced computer tomography, magnetic resonance
imaging or transabdominal ultrasonography). In addition, the inclusion criteria were admission to
hospital within first 24 h from the onset of pain due to AP, and the written informed consent for the
study. Patients treated with anticoagulants due to pre-existing conditions, those with pre-existing
coagulopathies, as well as those with chronic pancreatitis, neoplasms, and chronic liver diseases
(cirrhosis or viral hepatitis) were excluded.
The blood samples for laboratory tests were collected twice: on admission, i.e., within first 24 h
from the onset of pain, and on Day 2 of hospital stay, i.e., at 48 h from the onset of pain as a symptom
of AP.
DIC was diagnosed according to ISTH score for overt DIC [24]. D-dimer was used as a marker
of fibrin formation. Moderately increased D-dimer concentrations were defined as 0.5–5 µg/mL (i.e.,
elevated up to 10-times above the reference limit), and severely increased as above 5 µg/mL.
The severity of AP was defined following 2012 revision of the Atlanta Classification [3]. MAP was
diagnosed when no organ failure, local or systemic complications occurred. MSAP was diagnosed
when a patient presented transient organ failure (resolving within 48 h), local (necrosis, acute necrotic
collection, walled-off pancreatic necrosis) or systemic complications (exacerbation of preexisting
conditions). SAP was diagnosed in patients with persistent (lasting longer than 48 h) organ failure.
The diagnosis of MAP, MSAP or SAP was based on the clinical evolution of AP during the hospital
stay of a patient. BISAP [25] and Glasgow [26] severity scores were calculated based on the assessment
of patients during first 24 h of AP.
Additional group of healthy volunteers were recruited in order to obtain reference values for the
non-routine laboratory tests, i.e., angiopoietin-2 and sFlt-1 in serum. The volunteers were men and
women without any known pancreatic, renal, or liver diseases, malignancies or autoimmune diseases,
without pregnancy in women, without thrombotic disorders in anamnesis, and with serum C-reactive
protein concentrations below 3 mg/L. They provided written informed consent for the study. Single
venous blood samples were collected from healthy volunteers into serum tubes.
The study protocol was approved by the Bioethics Committee of the Jagiellonian University
(approval no. KBET/247/B/2013, permission date 28 November 2013, and 122.6120.242.2015,
permission date 22 November 2015).
4.2. Laboratory Tests
Plasma was prepared by centrifugation of sodium citrate–anticoagulated venous blood (1 volume
of citrate per 9 volumes of blood), within 20 min from blood collection. The concentrations of D-dimer,
fibrinogen, as well as prothrombin time and APTT were measured on the day of blood collection,
using Coatron A4 automated hemostasis analyzer (TECO Medical Instruments, Neufahrn, Germany).
The reference ranges for the tests, as provided by the laboratory, were as following: <0.5 µg/mL for
D-dimer, 2–4 g/L for fibrinogen, 11.4–15.5 s for prothrombin time and 26–39 s for APTT.
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EDTA–anticoagulated full venous blood was used to perform complete blood counts, including
platelet counts. Blood counts were performed on the day of blood collection, with the use of Sysmex
XE 2100 analyzer (Sysmex Corporation, Kobe, Japan). The laboratory reference range for platelet count
was 150 × 103/µL–350 × 103/µL.
The concentrations of C-reactive protein, glucose, creatinine, urea, bilirubin, albumin, calcium,
and amylase activity were measured in serum on the day of blood collection, using automated analyzer
Cobas 6000 (Roche Diagnostics, Basel, Switzerland).
All the above tests were performed in the Department of Laboratory Diagnostics, District Hospital
in Sucha Beskidzka, Poland.
Serum for angiopoietin-2 and sFlt-1 measurements was obtained by centrifugation of venous
blood. The blood samples collected from AP patients and from healthy volunteers were proceeded
in the same way. Serum samples were aliquoted and kept frozen at −70 ◦C until assayed (no longer
than three months). Angiopoietin-2 was measured with the Quantikine ELISA Human Angiopoietin-2
immunoassay (R&D Systems, McKinley Place, MN, USA) in the Department of Diagnostics, Chair of
Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland. The concentrations
of sFlt-1 were measured by electrochemiluminescence immunoassay using Cobas 8000 analyzer
(Roche Diagnostics, Mannheim, Germany) in the Department of Diagnostics, University Hospital,
Kraków, Poland.
4.3. Statistical Analysis
Data were reported as numbers (percentage) for categories, median (lower-upper quartile)
for non-normally distributed quantitative variables, and mean ± standard deviation for normally
distributed quantitative variables (as tested with Shapiro–Wilk test). Chi-squared test, Mann–Whitney
test, and unpaired t-test were used to study differences between groups, respectively. Logistic regression
was used to check whether the differences between patients and controls were independent of age.
Right-skewed variables were log-transformed before calculating Pearson’s correlation coefficients and
before including in multiple linear regression. ROC curves were used to assess diagnostic utility of
studied tests, and the results are expressed as area under the ROC curve ± standard error. Results were
considered significant at p-value below 0.05. The calculations were made with the use of Statistica 12
software package (StatSoft, Tulsa, OK, USA).
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2. Párniczky, A.; Kui, B.; Szentesi, A.; Balázs, A.; Szűcs, Á.; Mosztbacher, D.; Czimmer, J.; Sarlós, P.; Bajor, J.;
Gódi, S.; et al. Prospective, multicentre, nationwide clinical data from 600 cases of acute pancreatitis.
PLoS ONE 2016, 11, e0165309. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 753 13 of 15
3. Banks, P.A.; Bollen, T.L.; Dervenis, C.; Gooszen, H.G.; Johnson, C.D.; Sarr, M.G.; Tsiotos, G.G.; Vege, S.S.
Classification of acute pancreatitis–2012: Revision of the Atlanta classification and definitions by international
consensus. Gut 2013, 62, 102–111. [CrossRef] [PubMed]
4. Afghani, E.; Pandol, S.J.; Shimosegawa, T.; Sutton, R.; Wu, B.U.; Vege, S.S.; Gorelick, F.; Hirota, M.; Windsor, J.;
Lo, S.K.; et al. Acute pancreatitis-progress and challenges: A report on an international symposium. Pancreas
2015, 44, 1195–1210. [CrossRef] [PubMed]
5. Whitcomb, D.C.; Muddana, V.; Langmead, C.J.; Houghton, F.D.; Guenther, A.; Eagon, P.K.; Mayerle, J.;
Aghdassi, A.A.; Weiss, F.U.; Evans, A.; et al. Angiopoietin-2, a regulator of vascular permeability in
inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United
States and Germany. Am. J. Gastroenterol. 2010, 105, 2287–2292. [CrossRef] [PubMed]
6. Buddingh, K.T.; Koudstaal, L.G.; van Santvoort, H.C.; Besselink, M.G.; Timmer, R.; Rosman, C.; van Goor, H.;
Nijmeijer, R.M.; Gooszen, H.; Leuvenink, H.G.D.; et al. Early angiopoietin-2 levels after onset predict the
advent of severe pancreatitis, multiple organ failure, and infectious complications in patients with acute
pancreatitis. J. Am. Coll. Surg. 2014, 218, 26–32. [CrossRef] [PubMed]
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